Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.6 EUR | 0.00% | +0.78% | -3.70% |
May. 09 | Uniphar says trading in line, reports good start to 2024 | AN |
May. 09 | Uniphar Logs Organic Gross Profit Growth in FY23, Affirms FY24 Guidance | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.35 for the 2024 fiscal year.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.70% | 768M | C+ | ||
+19.13% | 71.7B | C+ | ||
-3.66% | 23.73B | C+ | ||
+9.54% | 9.01B | C | ||
+11.24% | 8.72B | B | ||
-18.91% | 8.29B | B- | ||
+16.00% | 5B | B- | ||
+17.83% | 4.48B | B+ | ||
-2.11% | 4.08B | B- | ||
-1.72% | 3.92B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UPR Stock
- Ratings Uniphar plc